` RGS (Regeneus Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

RGS
vs
S
S&P/ASX 300

Over the past 12 months, RGS has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +7% growth.

Stocks Performance
RGS vs S&P/ASX 300

Loading
RGS
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
RGS vs S&P/ASX 300

Loading
RGS
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
RGS vs S&P/ASX 300

Loading
RGS
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Regeneus Ltd vs Peers

S&P/ASX 300
RGS
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Regeneus Ltd
Glance View

Market Cap
5.5m AUD
Industry
Biotechnology

Regeneus Ltd. is regenerative medicine company. The firm uses stem cell technologies to develop cell-based therapies. Its therapeutic areas include knee osteoarthritis, neuropathic pain and skin inflammation. The Company’s platform technologies consist of Progenza and Sygenus. The Progenza is a cellular therapy targeting pain and inflammation, which uses the secretome to improve Mesenchymal Signalling Cells (MSCs).The Progenza repairs local damaged tissue, such as cartilage tissue commonly found in joints like the knees and elbows. The Sygenus is a cell-free topical serum and gel treatment for pain and inflammation derived from Adipose MSCs. The Sygenus consists of selective bioactive molecules from the secretome. The company reduces pain and inflammation, while accelerating tissue healing and repair.

RGS Intrinsic Value
Not Available
Back to Top